Genmab A/S

CPSE:GMAB 주식 리포트

시가총액: DKK 106.5b

Genmab 과거 순이익 실적

과거 기준 점검 2/6

Genmab은 연평균 18%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 13.3% 증가했습니다. 매출은 연평균 23.6%의 비율로 증가했습니다. Genmab의 자기자본이익률은 14.4%이고 순이익률은 21%입니다.

핵심 정보

18.05%

순이익 성장률

19.10%

주당순이익(EPS) 성장률

Biotechs 산업 성장률18.72%
매출 성장률23.62%
자기자본이익률14.45%
순이익률21.05%
다음 순이익 업데이트06 Aug 2026

최근 과거 실적 업데이트

분석 기사 • May 15

There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...

Recent updates

내러티브 업데이트 • May 26

GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality

Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.
분석 기사 • May 15

There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...
분석 기사 • May 11

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
내러티브 업데이트 • Apr 29

GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook

Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
내러티브 업데이트 • Apr 15

GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook

Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.
내러티브 업데이트 • Mar 31

GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile

Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.
내러티브 업데이트 • Mar 17

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
내러티브 업데이트 • Mar 03

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
내러티브 업데이트 • Feb 17

GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook

Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.
내러티브 업데이트 • Feb 02

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
내러티브 업데이트 • Jan 19

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
내러티브 업데이트 • Jan 05

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
내러티브 업데이트 • Dec 14

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
내러티브 업데이트 • Nov 29

GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook

Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.
내러티브 업데이트 • Nov 15

GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance

Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.
내러티브 업데이트 • Nov 01

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain

Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.
내러티브 업데이트 • Oct 18

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.
내러티브 업데이트 • Oct 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.
분석 기사 • Sep 24

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
내러티브 업데이트 • Sep 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.
분석 기사 • Jul 31

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
User avatar
새로운 내러티브 • Nov 11

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

매출 및 비용 세부 내역

Genmab가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

CPSE:GMAB 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Mar 263,9018216661,687
31 Dec 253,7209636261,606
30 Sep 253,8461,5836431,567
30 Jun 253,6471,3716241,550
31 Mar 253,2331,1365501,438
31 Dec 243,1211,1335491,414
30 Sep 242,9647025191,349
30 Jun 242,7437985011,276
31 Mar 242,5767915041,187
01 Jan 242,3906314781,107
30 Sep 232,3895904661,033
30 Jun 232,378680453979
31 Mar 232,216757422890
31 Dec 222,088785385801
30 Sep 221,580745299688
30 Jun 221,438558268683
31 Mar 221,342354228667
31 Dec 211,288452196640
30 Sep 211,232448156590
30 Jun 211,168401134541
31 Mar 211,703880119512
31 Dec 201,660781108515
30 Sep 201,73688986453
30 Jun 201,55985373417
31 Mar 2083734956378
31 Dec 1980632551358
30 Sep 1953222342317
30 Jun 1948717839291
31 Mar 1944120236250
31 Dec 1846422633220
30 Sep 1843722230191
30 Jun 1839719428174
31 Mar 1846221326164
31 Dec 1738117824137
30 Sep 1736118421126
30 Jun 1735620819110
31 Mar 1727217416101
31 Dec 162571681494
30 Sep 162211111597
30 Jun 162051021490
31 Mar 16183821481
31 Dec 151651111371
30 Sep 15116661466
30 Jun 15115691466

양질의 수익: GMAB는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: GMAB의 현재 순 이익률 (21%)은 지난해 (35.1%)보다 낮습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: GMAB의 수익은 지난 5년 동안 연평균 18% 증가했습니다.

성장 가속화: GMAB은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.

수익 대 산업: GMAB은 지난 1년 동안 수익이 감소(-27.7%)하여 Biotechs 업계 평균(21.7%)과 비교하기 어렵습니다.

자기자본이익률

높은 ROE: GMAB의 자본 수익률(14.4%)은 낮음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/27 22:35
종가2026/05/27 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Genmab A/S는 41명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays